

Mobile Phone Use and Risk of Tumors: A Meta-Analysis

Seung-Kwon Myung, Woong Ju, Diana D. McDonnell, Yeon Ji Lee, Gene Kazinets, Chih-Tao Cheng, and Joel M. Moskowitz

ABSTRACT

Purpose

Case-control studies have reported inconsistent findings regarding the association between mobile phone use and tumor risk. We investigated these associations using a meta-analysis.

Methods

We searched MEDLINE (PubMed), EMBASE, and the Cochrane Library in August 2008. Two evaluators independently reviewed and selected articles based on predetermined selection criteria.

Results

Of 465 articles meeting our initial criteria, 23 case-control studies, which involved 37,916 participants (12,344 patient cases and 25,572 controls), were included in the final analyses. Compared with never or rarely having used a mobile phone, the odds ratio for overall use was 0.98 for malignant and benign tumors (95% CI, 0.89 to 1.07) in a random-effects meta-analysis of all 23 studies. However, a significant positive association (harmful effect) was observed in a random-effects meta-analysis of eight studies using blinding, whereas a significant negative association (protective effect) was observed in a fixed-effects meta-analysis of 15 studies not using blinding. Mobile phone use of 10 years or longer was associated with a risk of tumors in 13 studies reporting this association (odds ratio = 1.18; 95% CI, 1.04 to 1.34). Further, these findings were also observed in the subgroup analyses by methodologic quality of study. Blinding and methodologic quality of study were strongly associated with the research group.

Conclusion

The current study found that there is possible evidence linking mobile phone use to an increased risk of tumors from a meta-analysis of low-biased case-control studies. Prospective cohort studies providing a higher level of evidence are needed.

J Clin Oncol 27. © 2009 by American Society of Clinical Oncology

INTRODUCTION

The worldwide use of mobile phones has rapidly increased over the past decade. According to data from the International Telecommunication Union, the number of worldwide mobile cellular subscribers was 12.2 per 100 inhabitants in 2000 but grew to 49.5 per 100 inhabitants in 2007.¹ With the increasing use of mobile phones (ie, cellular phones and cordless phones), concern has been raised about the possible carcinogenic effects as a result of exposure to radiofrequency electromagnetic fields (EMFs) emitted from cellular phones ranging from 800 to 2,000 MHz,^{2,3} which fall in the microwave spectrum. Although some in vitro studies reported the potential effects of high-frequency EMFs on cell proliferation and activation of oncogene transcription,⁴⁻⁶ those biologic effects and mechanisms in developing neoplasm remain unclear. Over the past decade, epi-

miologic studies (mainly case-control) also have reported the relationships between the use of mobile phones and malignant or benign tumors such as brain tumors, head and neck tumors, non-Hodgkin's lymphoma, and testicular cancer.⁷⁻²⁸

Some case-control studies have suggested a positive (ie, harmful) association between the use of mobile phones and the risk of tumors,^{7,10-12,15-18,23,25,27} whereas other case-control studies have reported no significant association.^{8,9,11,13,14,19-22,24,26,28} Also, the only retrospective cohort study reported no evidence for the association among either short-term or long-term users.^{29,30}

Regarding the conflicting scientific evidence, three meta-analyses reported no association or a slight increased risk.³¹⁻³³ However, these meta-analyses involved only brain tumors. In the current study, we investigated the associations between the use of mobile phones and the risk of tumors, including both malignant and benign conditions, via a meta-analysis of case-control studies.

From the Smoking Cessation Clinic, Center for Cancer Prevention and Detection; Division of Cancer Prevention, National Cancer Control Research Institute, National Cancer Center, Goyang; Department of Obstetrics and Gynecology, School of Medicine, Ewha Womans University; Department of Family Medicine, Seoul National University Hospital, Seoul, Republic of Korea; and Center for Family and Community Health, School of Public Health, University of California, Berkeley, Berkeley, CA.

Submitted December 19, 2008; accepted June 9, 2009; published online ahead of print at www.jco.org on October 13, 2009.

Written on behalf of the Korean Meta-Analysis (KORMA) Study Group.

Supported in part by the Centers for Disease Control and Prevention through Cooperative Agreement No. U48/DP000033 (D.D.M., G.K., J.M.M.).

The contents of the article are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: Seung-Kwon Myung, MD, MS, 111 Jungbalsan-ro, Ilsandong-gu, Goyang, Gyeonggi-do, 410-769, Republic of Korea; e-mail: msk@ncc.re.kr.

© 2009 by American Society of Clinical Oncology

0732-183X/09/2799-1/\$20.00

DOI: 10.1200/JCO.2008.21.6366

METHODS

Literature Search

We searched MEDLINE (PubMed; 1968 to August 2008), EMBASE (1977 to August 2008), and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (1953 to August 2008) using common keywords related to mobile phones and tumor or cancer. The keywords were as follows: “mobile phones,” “cellular phones,” or “cordless phones” and “tumors” or “cancer.” We also reviewed the bibliographies of relevant articles to locate additional publications. The language of publication was not restricted.

Selection Criteria

We included epidemiologic studies that met all of the following criteria: case-control study (to date, no randomized controlled trials and only one retrospective cohort study published in four different articles have been reported; therefore, we included only case-control studies in this study); investigated the associations between the use of mobile phones, cellular phones, or cordless phones and malignant or benign tumors; reported outcome measures with adjusted odds ratios and 95% CIs, crude odds ratios and 95% CIs, or values in cells of a 2×2 table (from which odds ratios could be calculated). If data were duplicated or shared in more than one study, the first published or more comprehensive study was included in the analysis.

Selection of Relevant Studies

Two of the authors (S.-K.M. and W.J.) independently evaluated eligibility of all studies retrieved from the databases based on the predetermined selection criteria. Disagreements between evaluators were resolved by discussion or in consultation with a third author (D.D.M.).

Assessment of Methodologic Quality

We assessed the methodologic quality of included studies based on the Newcastle-Ottawa Scale (NOS) for quality of case-control studies in meta-analyses.³⁴ A star system of the NOS (range, 0 to 9 stars) has been developed for the assessment. In the current study, we considered a study awarded 7 or more stars as a high-quality study because standard criteria have not been established. The mean value for the 23 studies assessed was 6.3 stars.

Main and Subgroup Analyses

We investigated the association between the use of mobile phones (use v never or rarely use, if possible) and the overall risk of all tumors by using adjusted data as a main analysis. We also performed subgroup analyses by whether the status of patient cases and controls was blinded at interview (blinded or not blinded/no description), research group (adjusted or crude data), methodologic quality (high or low quality), type of tumor, malignancy of tumor (malignant or benign), type of mobile phone (analog or digital), laterality of tumor (ipsilateral or contralateral), and type of case-control study (hospital based or population based). Furthermore, we investigated the association between long-term mobile phone use (≥ 10 years) and the risk of tumors, including subgroup analyses by the factors listed earlier.

Statistical Analyses

To compute a pooled odds ratio with 95% CI, we used the adjusted odds ratio and 95% CIs reported in each article whenever possible. We examined heterogeneity in results across studies using Higgins I^2 , which measures the percentage of total variation across studies.³⁵ We considered an I^2 value of greater than 50% as indicative of substantial heterogeneity.

When substantial heterogeneity was not observed, the pooled estimate calculated based on the fixed-effects model was reported using the Woolf's (inverse variance) method. When substantial heterogeneity was observed, the pooled estimate calculated based on the random-effects model was reported using the DerSimonian and Laird method.³⁶

We evaluated publication bias of the studies included in the final analysis using Begg's funnel plot and Egger's test. If publication bias exists, Begg's funnel plot is asymmetric or the P value is less than .05 by Egger's test. Also, a meta-regression analysis was performed to assess the effect of subgroups and study characteristics, such as research group, year of publication, type of tumor, and study design, on the study results. Blinding and methodologic

quality were excluded because of multicollinearity with research group. We used Stata SE version 10.0 software package (StataCorp, College Station, TX) for statistical analysis.

RESULTS

Identification of Relevant Studies

Figure 1 shows a flow diagram of how we identified relevant studies. A total of 465 articles were identified by searching three databases and hand-searching relevant bibliographies. We excluded 135 duplicate articles and an additional 287 articles that did not satisfy the selection criteria. After reviewing the full texts of the remaining 43 articles, 21 articles³⁷⁻⁵⁷ were excluded because of several reasons, as shown in Figure 1. The remaining 23 case-control studies from 22 articles⁷⁻²⁸ were included in the final analysis (the study by Auvinen et al¹¹ was considered as two individual case-control studies).

Characteristics of Studies Included in the Final Analysis

In the 23 case-control studies, we identified a total of 37,916 participants (12,344 patient cases and 25,572 controls). For studies reporting age and sex, the mean age was 52.6 years (range, 18 to 90 years), and 51% of the participants were women.

Appendix Table A1 (online only) shows the general characteristics of the 23 case-control studies (22 articles) included in the final analysis. The percentage of study participants who reported having used a mobile phone was 43.5% among the patient cases and 45.2% among the controls (data not shown in Appendix Table A1).




Fig 1. Flow diagram for identification of relevant case-control studies. (*) One article (Auvinen et al¹¹) was divided into two studies because it involved two different types of tumors.




Fig 2. Overall use of mobile phones and the risk of tumors in a random-effects model meta-analysis of case-control studies⁷⁻²⁸ by the use of blinding at an interview for exposure measurements (n = 23). OR, odds ratio; Hardell et al (2005, I) indicates reference 15; Hardell et al (2005, N) indicates reference 16.

Overall Use of Mobile Phones and Risk of Tumors

As shown in Figure 2, the overall use of mobile phones (use v never or rarely use) was not significantly associated with the risk of tumors in a random-effects model meta-analysis of all 23 case-control studies (odds ratio = 0.98; 95% CI, 0.89 to 1.07). However, a significant positive association (ie, harmful effect) was observed in eight studies^{7,12,14-16,18,23} and one study by another group¹⁰) using blinding (odds ratio = 1.17; 95% CI, 1.02 to 1.36), whereas a significant negative association (ie, protective effect) was observed in 15 studies (nine INTERPHONE-related studies^{17,20-22,24-28} and six studies by other groups^{8,9,11,13,19}) not using blinding (odds ratio = 0.85; 95% CI, 0.80 to 0.91). No publication bias was observed in the selected studies (Begg's funnel plot was symmetric; Egger's test, P for bias = .21; Fig 3).




Fig 3. Begg's funnel plots and Egger's test for identifying publication bias (P = .21) in a meta-analysis of case-control studies⁷⁻²⁸ (n = 23). OR, odds ratio.

Table 1 shows the methodologic quality of studies included in the final analysis. The range of quality scores was 5 to 8; the average score was 6.3. The high-quality studies (score of ≥ 7) included all seven of the studies by Hardell et al, one INTERPHONE-related study, and two studies by other groups. The low-quality studies (score of < 7) included eight INTERPHONE-related studies and six studies by other groups.

A subgroup meta-analysis by research group showed a significant positive association for the seven studies reported by Hardell et al but a significant negative association for nine INTERPHONE-related studies (Table 2). When using crude data, a significant association was not found in any of the 23 studies or in subgroup analyses by research group.

Subgroup meta-analyses by methodologic quality of study revealed a significant positive association in the high-quality studies (odds ratio = 1.09; 95% CI, 1.01 to 1.18), whereas a negative association was observed in the low-quality studies. In subgroup meta-analyses by malignancy of tumor, no significant association was observed for malignant tumors. However, a significant negative association was observed for benign tumors. Neither the use of analog phones nor the use of digital phones was associated with the risk of tumors. The ipsilateral use of mobile phones (ie, on the same side of the head where the tumor exists) was marginally associated with the risk of tumors in the 12 studies reporting tumor laterality.

Mobile Phone Use of 10 Years or Longer and Risk of Tumors

Among the 23 studies, there was a significant positive association between mobile phone use of 10 years or longer and the risk of tumors in a fixed-effects meta-analysis of 13 studies reporting this association (odds ratio = 1.18; 95% CI, 1.04 to 1.34; Fig 4; Appendix Table A2, online only). As for blinding, a fixed-effects

Table 1. Methodologic Quality of Studies Included in the Final Analysis Based on the Newcastle-Ottawa Scale for Assessing the Quality of Case-Control Studies

Study	Selection (score)				Comparability (score)	Exposure (score)			Total Score†
	Adequate Definition of Patient Cases	Representativeness of Patient Cases	Selection of Controls	Definition of Controls	Control for Important Factor or Additional Factor	Ascertainment of Exposure (blinding)	Same Method of Ascertainment for Participants	Nonresponse Rate*	
Hardell et al ⁷	1	1	1	0	1	1	1	1	7
Muscat et al ⁸	1	0	0	1	2	0	1	0	5
Inskip et al ⁹	1	0	0	1	2	0	1	0	5
Stang et al ¹⁰ (hospital based)	1	1	0	0	2	1	1	0	6
Stang et al ¹⁰ (population based)	1	1	1	0	2	1	1	0	7
Auvinen et al ¹¹ (1)	1	1	1	1	1	0	1	0	6
Auvinen et al ¹¹ (2)	1	1	1	1	1	0	1	0	6
Hardell et al ¹²	1	1	1	0	2	1	1	0	7
Warren et al ¹³	1	1	0	1	1	0	1	0	5
Hardell et al ¹⁴	1	1	1	0	1	1	1	1	7
Hardell et al ¹⁵	1	1	1	0	2	1	1	1	8
Hardell et al ¹⁶	1	1	1	0	2	1	1	0	7
Schoemaker et al ¹⁷	1	1	1	1	2	0	1	0	7
Hardell et al ¹⁸	1	1	1	0	2	1	1	1	8
Linnet et al ¹⁹	1	1	1	1	2	0	1	0	7
Lönn et al ²⁰	1	1	1	0	2	0	1	0	6
Schüz et al ²¹	1	1	1	0	2	0	1	0	6
Takebayashi et al ²²	1	1	1	0	2	0	1	0	6
Hardell et al ²³	1	1	1	0	2	1	1	1	8
Hours et al ²⁴	1	1	1	0	2	0	1	0	6
Lahkola et al ²⁵	1	1	1	0	2	0	1	0	6
Lahkola et al ²⁶	1	1	1	0	1	0	1	0	5
Sadetzki et al ²⁷	1	1	1	0	1	0	1	0	5
Takebayashi et al ²⁸	1	1	1	0	2	0	1	0	6

*When there was no significant difference in the response rate between both groups by using a χ^2 test ($P > .05$), one point was awarded.
†Total score could range from 0 to 9 points.

meta-analysis of the seven blinded studies showed a positive association, whereas a fixed-effects meta-analysis of the six unblinded studies showed no significant association.

In the subgroup meta-analyses by methodologic quality, a significant positive association was found in the eight high-quality studies but not in the seven low-quality studies. With regard to tumor malignancy, mobile phone use of 10 years or longer was significantly positively associated with the risk of benign tumors but not with the risk of malignant tumors.

The use of analog phones for 10 years or longer was positively associated with the risk of tumors. However, further subgroup analyses by research group showed a significant association only in the studies by Hardell et al.^{7,12,14-16,18,23} Regarding the laterality of tumors and mobile phone use of 10 years or longer, a significantly increased odds ratio was identified for ipsilateral use but not for contralateral use.

Overall Mobile Phone Use and the Risk of Brain Tumors

As shown in Appendix Table A3 (online only), no significant association was observed in a meta-analysis of 15 studies involving brain tumors. For meningiomas, a preventive effect was observed, and this effect was largely a result of a decreased odds ratio in INTERPHONE-related studies.

A significant negative association was found in a meta-analysis of studies involving benign brain tumors, and this was largely a result of a decreased odds ratio in the INTERPHONE-related studies. No association between mobile phone use and tumor risk was observed in both analog phone users and digital phone users. With regard to research group, blinding, and methodologic quality, similar findings to those of the subgroup analyses were observed (ie, a significant association in the studies by Hardell et al, a negative association in INTERPHONE-related studies, and no association in the studies by other groups).

Overall Mobile Phone Use and the Risk of Other Tumors

Appendix Table A4 (online only) shows the findings of the subgroup analyses of studies involving tumors other than brain tumors. Unlike brain tumors, all of the subgroup meta-analyses based on various factors showed no significant associations between overall mobile phone use and the risk of other tumors.

Meta-Regression Analysis

A meta-regression analysis showed that only the variable indicating research group was significantly associated with the study results ($P = .001$). No significant association was observed for year of publication, type of tumor, or study design.

Table 2. Mobile Phone Use (v never or rarely use) and the Risk of Tumors in Subgroup Meta-Analyses

Factor	No. of Studies	Summary OR	95% CI of OR	Heterogeneity, I ² (%)	Model Used
All	23	0.98	0.89 to 1.07	59.7	Random effects
Research group					
Hardell et al*	7	1.15	1.01 to 1.32	52.1	Random effects
INTERPHONE†	9	0.83	0.77 to 0.89	0	Fixed effects
Other groups	7	0.99	0.86 to 1.14	30.6	Fixed effects
Research group (crude data)	23	0.97	0.87 to 1.08	73.6	Random effects
Hardell et al	7	1.14	0.96 to 1.35	71.0	Random effects
INTERPHONE	9	0.88	0.75 to 1.03	79.8	Random effects
Other groups	7	0.90	0.79 to 1.03	22.6	Fixed effects
Methodologic quality					
High (low bias: ≥ 7 points)*	10	1.09	1.01 to 1.18	46.3	Fixed effects
Hardell et al*	7	1.15	1.00 to 1.32	52.1	Random effects
INTERPHONE	1	0.90	0.70 to 1.10	NA	NA
Other group	2	1.02	0.75 to 1.38	0	Fixed effects
Low (high bias: < 7 points)†	14	0.85	0.79 to 0.91	5.7	Fixed effects
INTERPHONE†	8	0.82	0.76 to 0.88	0	Fixed effects
Other groups	6	0.97	0.83 to 1.14	24.2	Fixed effects
Malignancy of tumor					
Malignant	15	1.00	0.89 to 1.13	52.0	Random effects
Hardell et al	6	1.11	0.96 to 1.29	50.5	Random effects
INTERPHONE†	4	0.78	0.67 to 0.91	0	Fixed effects
Other groups	5	0.97	0.80 to 1.18	19.6	Fixed effects
Benign	15	0.87	0.80 to 0.95	20.7	Fixed effects
Hardell et al	4	1.17	0.97 to 1.42	3.8	Fixed effects
INTERPHONE†	8	0.81	0.73 to 0.90	0	Fixed effects
Other groups	3	0.82	0.61 to 1.11	0	Fixed effects
Type of mobile phone					
Analog	12	0.96	0.87 to 1.07	49.9	Fixed effects
Hardell et al	7	1.04	0.89 to 1.22	34.5	Fixed effects
INTERPHONE†	3	0.84	0.72 to 0.96	0	Fixed effects
Other groups*	2	1.55	1.08 to 2.2	0	Fixed effects
Digital	14	0.95	0.84 to 1.08	55.8	Random effects
Hardell et al	7	1.10	0.97 to 1.24	12.7	Fixed effects
INTERPHONE†	5	0.78	0.71 to 0.85	0	Fixed effects
Other groups	2	0.93	0.55 to 1.59	0	Fixed effects
Laterality of tumor					
Ipsilateral	12	1.22	0.99 to 1.51	85.9	Random effects
Hardell et al*	4	1.80	1.24 to 2.62	84.9	Random effects
INTERPHONE	8	1.00	0.91 to 1.10	37.0	Fixed effects
Contralateral	11	0.94	0.77 to 1.15	82.3	Random effects
Hardell et al	3	1.31	0.74 to 2.31	93.0	Random effects
INTERPHONE†	8	0.81	0.74 to 0.89	48.2	Fixed effects
Type of case-control study					
Hospital based (all other groups)	4	0.89	0.74 to 1.07	0.0	Fixed effects
Population based	20	0.99	0.89 to 1.09	61.8	Random effects
Hardell et al*	7	1.15	1.01 to 1.32	52.1	Random effects
INTERPHONE†	9	0.83	0.77 to 0.89	0	Fixed effects
Other groups	4	1.14	0.91 to 1.43	0	Fixed effects

Abbreviations: OR, odds ratio; NA, not applicable.

*Statistically significant positive association.

†Statistically significant negative association.

DISCUSSION

We found that the use of mobile phones was associated with a mild increased risk of tumors, when compared with never or rare use of mobile phones, in the meta-analyses of case-control studies that used blinding or had a high methodologic quality, whereas no significant association was observed in a meta-analysis of all included studies.

Also, mobile phone use of 10 years or longer increased the risk of tumors in a meta-analysis of all the studies reporting this association. Furthermore, in the subgroup meta-analyses by research group, a distinct pattern of the findings was observed as follows: a positive association (ie, harmful effect) in the Hardell et al studies, a negative association (ie, protective effect) in the INTERPHONE-related studies, and no association in other research groups' studies.




Fig 4. Mobile phone use of 10 years or longer and the risk of tumors in a fixed-effects model meta-analysis of case-control studies^{7,12,14-18,20,21,23,25-27} by the use of blinding at an interview for exposure measurements (n = 13). OR, odds ratio; Hardell et al (2005, I) indicates reference 15; Hardell et al (2005, N) indicates reference 16.

These findings were strongly related to the fact that all of the studies by Hardell et al used blinding to the status of patient cases or controls at the interview and were categorized as having a high methodologic quality when assessed based on the NOS, whereas most of the INTERPHONE-related studies and studies by other groups did not use blinding and were thus categorized as having low methodologic quality. The blinding item is one of the eight items in the NOS. Nevertheless, we also used the blinding item independently as well as the NOS as a kind of indicator of the quality assessment for the studies because the NOS has not been fully validated and the blinding item was considered an important factor that affects the findings of each study.

Also, similar findings concerning the research group were observed in subgroup analyses by malignancy of tumor, type of laterality, type of case-control study, and type of tumor. Regarding type of brain tumor, a negative association was observed for meningiomas but not for gliomas and acoustic neuromas, and this negative association was largely a result of a decreased odds ratio in INTERPHONE-related studies.

Besides blinding and methodologic quality of studies, we should consider two potential biases regarding the differences we found by research groups—recall bias and selection bias, both of which have been described in detail elsewhere.⁵⁷ In a validation study of short-term recall for mobile phone use, Vrijheid et al⁵⁸ reported that substantial random errors could reduce the power of the INTERPHONE study to detect an increased risk of brain and parotid gland tumors. Furthermore, they found that random errors and selection bias could lead to finding a decreased risk of brain cancer through Monte-Carlo simulation using the INTERPHONE data.⁵⁷ These findings may explain why a significant decreased risk for tumor was observed among mobile phone users in the INTERPHONE-related studies.

To reduce recall and selection biases, a prospective cohort study is needed. A large nationwide Danish retrospective cohort study,^{29,30,59,60} which is the only cohort study published so far, re-

ported that there was no evidence for an association between cellular telephone use and tumor risk based on standardized incidence ratios for cancer that were calculated from the cancer prevalence among cellular telephone subscribers compared with the rates expected among the general population. However, this study relied on phone subscription information and did not evaluate actual exposure to mobile phones.

If we do not consider subgroup meta-analyses by research group or blinding/methodologic quality of studies, our overall results are similar to the previous three meta-analyses³¹⁻³³ evaluating mobile phone use and the risk of brain tumor, which reported no overall increased risk of brain tumors among cellular phone users and slightly increased risk of brain tumors for use of 10 years or longer.

Unlike the previous meta-analyses, however, we found significant associations between mobile phone use and risk of tumors in low-biased, case-control studies, which were mostly studies by Hardell et al, when performing subgroup analyses by use of blinding or the methodologic quality of studies. That is, the methodologic quality of study and blinding were strongly related to both the research group and the studies' findings. In particular, among the items of the NOS for assessing the quality of case-control studies, blinding and response rates between patient cases and controls were the major contributing factors to differentiate a high-quality study from a low-quality study. All seven studies by Hardell et al^{7,12,14-16,18,23} used blinding, and five of them showed no significant difference in response rates between patient cases and controls, whereas INTERPHONE-related studies and the other studies, except for the study by Stang et al,¹⁰ did not use blinding and showed a significant difference in response rates.

We feel the need to mention the funding sources for each research group because it is possible that these may have influenced the respective study designs and results. According to the acknowledgments that appeared in the publications, the Hardell et al group was supported by grants from the Swedish Work Environment Fund, Orebro Cancer Fund, Orebro University Hospital Cancer Fund, and

so on. Most of the INTERPHONE-related studies were mainly supported by the Quality of Life and Management of Living Resources program of the European Union and the International Union Against Cancer; the International Union Against Cancer received funds for those studies from the Mobile Manufacturers Forum and the Global System for Mobile Communication Association.

The association between mobile phone use and tumor risk also remains unresolved in experimental studies using *in vivo* animal models or *in vitro* cancer cell lines. Although it has been established that low-frequency EMF (microwave) exposure induces biologic change of cytoplasmic membranes, nuclear levels, and specific gene levels,^{6,61-63} the effect of high-frequency EMF exposure on health is still controversial.⁶⁴⁻⁷⁰

Our study has several limitations. First, it does not provide the highest level of evidence because only case-control studies were involved. As mentioned previously, recall bias and selection bias might reduce the quality of mobile phone exposure data and, therefore, cause a spurious association. Second, we did not explore potential confounding factors in the studies by Hardell et al^{7,12,14-16,18,23} that reported positive results not found by other study groups. Those issues need to be explored in future studies.

In sum, in our meta-analyses of case-control studies, we found evidence linking mobile phone use to an increased risk of tumors,

especially among users of 10 or more years. Furthermore, we found a large discrepancy in the association between mobile phone use and tumor risk by research group, which is confounded with the methodologic quality of the research. Our findings should be confirmed in prospective cohort studies to provide a higher level of evidence.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

Conception and design: Seung-Kwon Myung, Woong Ju

Administrative support: Seung-Kwon Myung, Woong Ju

Provision of study materials or patients: Seung-Kwon Myung

Collection and assembly of data: Seung-Kwon Myung, Woong Ju,

Diana D. McDonnell, Yeon Ji Lee, Gene Kazinets, Chih-Tao Cheng

Data analysis and interpretation: Seung-Kwon Myung, Woong Ju,

Diana D. McDonnell, Yeon Ji Lee, Gene Kazinets, Chih-Tao Cheng,

Joel M. Moskowitz

Manuscript writing: Seung-Kwon Myung, Diana D. McDonnell,

Joel M. Moskowitz

Final approval of manuscript: Seung-Kwon Myung

REFERENCES

- International Telecommunication Union: ITC statistics database. <http://www.itu.int/ITU-D/ICT-EYE/Indicators/Indicators.aspx#>
- Hardell L, Sage C: Biological effects from electromagnetic field exposure and public exposure standards. *Biomed Pharmacother* 62:104-109, 2008
- Health Protection Agency: Radiation: Mobile telephony and health background information. http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1195733852558?p=1158934607786
- Velizarov S, Raskmark P, Kwee S: The effects of radiofrequency fields on cell proliferation are non-thermal. *Bioelectrochem Bioenerg* 48:177-180, 1999
- Goswami PC, Albee LD, Parsian AJ, et al: Pro-oncogene mRNA levels and activities of multiple transcription factors in C3H 10T1/2 murine embryonic fibroblasts exposed to 835.62 and 847.74 MHz cellular telephone communication frequency radiation. *Radiat Res* 151:300-309, 1999
- Marinelli F, La Salsa D, Ciccio G, et al: Exposure to 900 MHz electromagnetic field induces an unbalance between pro-apoptotic and pro-survival signals in T-lymphoblastoid leukemia CCRF-CEM cells. *J Cell Physiol* 198:324-332, 2004
- Hardell L, Nasman A, Pahlson A, et al: Use of cellular telephones and the risk for brain tumours: A case-control study. *Int J Oncol* 15:113-116, 1999
- Muscat JE, Malkin MG, Thompson S, et al: Handheld cellular telephone use and risk of brain cancer. *JAMA* 284:3001-3007, 2000
- Inskip PD, Tarone RE, Hatch EE, et al: Cellular-telephone use and brain tumors. *N Engl J Med* 344:79-86, 2001
- Stang A, Anastassiou G, Ahrens W, et al: The possible role of radiofrequency radiation in the development of uveal melanoma. *Epidemiology* 12:7-12, 2001
- Auvinen A, Hietanen M, Luukkonen R, et al: Brain tumors and salivary gland cancers among cellular telephone users. *Epidemiology* 13:356-359, 2002
- Hardell L, Hallquist A, Mild KH, et al: Cellular and cordless telephones and the risk for brain tumours. *Eur J Cancer Prev* 11:377-386, 2002
- Warren HG, Prevatt AA, Daly KA, et al: Cellular telephone use and risk of intratemporal facial nerve tumor. *Laryngoscope* 113:663-667, 2003
- Hardell L, Hallquist A, Hansson Mild K, et al: No association between the use of cellular or cordless telephones and salivary gland tumours. *Occup Environ Med* 61:675-679, 2004
- Hardell L, Eriksson M, Carlberg M, et al: Use of cellular or cordless telephones and the risk for non-Hodgkin's lymphoma. *Int Arch Occup Environ Health* 78:625-632, 2005
- Hardell L, Carlberg M, Hansson Mild K: Case-control study on cellular and cordless telephones and the risk for acoustic neuroma or meningioma in patients diagnosed 2000-2003. *Neuroepidemiology* 25:120-128, 2005
- Schoemaker MJ, Swerdlow AJ, Ahlbom A, et al: Mobile phone use and risk of acoustic neuroma: Results of the Interphone case-control study in five North European countries. *Br J Cancer* 93:842-848, 2005
- Hardell L, Carlberg M, Hansson Mild K: Case-control study of the association between the use of cellular and cordless telephones and malignant brain tumors diagnosed during 2000-2003. *Environ Res* 100:232-241, 2006
- Linet MS, Taggart T, Severson RK, et al: Cellular telephones and non-Hodgkin lymphoma. *Int J Cancer* 119:2382-2388, 2006
- Lönn S, Ahlbom A, Christensen HC, et al: Mobile phone use and risk of parotid gland tumor. *Am J Epidemiol* 164:637-643, 2006
- Schüz J, Bohler E, Berg G, et al: Cellular phones, cordless phones, and the risk of glioma and meningioma (Interphone Study Group, Germany). *Am J Epidemiol* 163:512-520, 2006
- Takebayashi T, Akiba S, Kikuchi Y, et al: Mobile phone use and acoustic neuroma risk in Japan. *Occup Environ Med* 63:802-807, 2006
- Hardell L, Carlberg M, Ohlson CG, et al: Use of cellular and cordless telephones and risk of testicular cancer. *Int J Androl* 30:115-122, 2007
- Hours M, Bernard M, Montestrucq L, et al: Cell phones and risk of brain and acoustic nerve tumours: The French INTERPHONE case-control study. *Rev Epidemiol Sante Publique* 55:321-332, 2007
- Lahkola A, Auvinen A, Raitanen J, et al: Mobile phone use and risk of glioma in 5 North European countries. *Int J Cancer* 120:1769-1775, 2007
- Lahkola A, Salminen T, Raitanen J, et al: Meningioma and mobile phone use—a collaborative case-control study in five North European countries. *Int J Epidemiol* 37:1304-1313, 2008
- Sadetzki S, Chetrit A, Jarus-Hakak A, et al: Cellular phone use and risk of benign and malignant parotid gland tumors—a nationwide case-control study. *Am J Epidemiol* 167:457-467, 2008
- Takebayashi T, Varsier N, Kikuchi Y, et al: Mobile phone use, exposure to radiofrequency electromagnetic field, and brain tumour: A case-control study. *Br J Cancer* 98:652-659, 2008
- Johansen C, Boice JD Jr, McLaughlin JK, et al: Cellular telephones and cancer—a nationwide cohort study in Denmark. *J Natl Cancer Inst* 93:203-207, 2001
- Schüz J, Jacobsen R, Olsen JH, et al: Cellular telephone use and cancer risk: Update of a nationwide Danish cohort. *J Natl Cancer Inst* 98:1707-1713, 2006
- Lahkola A, Tokola K, Auvinen A: Meta-analysis of mobile phone use and intracranial tumors. *Scand J Work Environ Health* 32:171-177, 2006
- Kan P, Simonsen SE, Lyon JL, et al: Cellular phone use and brain tumor: A meta-analysis. *J Neurooncol* 86:71-78, 2008

33. Hardell L, Carlberg M, Soderqvist F, et al: Meta-analysis of long-term mobile phone use and the association with brain tumours. *Int J Oncol* 32:1097-1103, 2008
34. Wells GA, Shea B, O'Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm
35. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. *Stat Med* 21:1539-1558, 2002
36. DerSimonian R, Laird N: Meta-analysis in clinical trials. *Control Clin Trials* 7:177-188, 1986
37. Hardell L, Nasman A, Pahlson A, et al: Case-control study on radiology work, medical x-ray investigations, and use of cellular telephones as risk factors for brain tumors. *MedGenMed* 2:E2, 2000
38. Hardell L, Hansson Mild K, Pahlson A, et al: Ionizing radiation, cellular telephones and the risk for brain tumours. *Eur J Cancer Prev* 10:523-529, 2001
39. Hardell L, Hansson Mild K, Carlberg M, et al: Case-control study on the use of cellular and cordless phones and the risk for malignant brain tumours. *Int J Radiat Biol* 78:931-936, 2002
40. Hardell L, Hansson Mild K, Carlberg M: Further aspects on cellular and cordless telephones and brain tumours. *Int J Oncol* 22:399-407, 2003
41. Hardell L, Hansson Mild K, Carlberg M, et al: Cellular and cordless telephone use and the association with brain tumors in different age groups. *Arch Environ Health* 59:132-137, 2004
42. Hardell L, Carlberg M, Hansson Mild K: Use of cellular telephones and brain tumour risk in urban and rural areas. *Occup Environ Med* 62:390-394, 2005
43. Schüz J, Bohler E, Schlehofer B, et al: Radio-frequency electromagnetic fields emitted from base stations of DECT cordless phones and the risk of glioma and meningioma (Interphone Study Group, Germany). *Radiat Res* 166:116-119, 2006
44. Blettner M, Schlehofer B, Samkange-Zeeb F, et al: Medical exposure to ionizing radiation and the risk of brain tumours: Interphone Study Group, Germany. *Eur J Cancer* 43:1990-1998, 2007
45. Muscat JE, Malkin MG, Shore RE, et al: Handheld cellular telephones and risk of acoustic neuroma. *Neurology* 58:1304-1306, 2002
46. Christensen HC, Schuz J, Kosteljanetz M, et al: Cellular telephone use and risk of acoustic neuroma. *Am J Epidemiol* 159:277-283, 2004
47. Lönn S, Ahlbom A, Hall P, et al: Mobile phone use and the risk of acoustic neuroma. *Epidemiology* 15:653-659, 2004
48. Christensen HC, Schuz J, Kosteljanetz M, et al: Cellular telephones and risk for brain tumors: A population-based, incident case-control study. *Neurology* 64:1189-1195, 2005
49. Lönn S, Ahlbom A, Hall P, et al: Long-term mobile phone use and brain tumor risk. *Am J Epidemiol* 161:526-535, 2005
50. Hardell L, Carlberg M, Hansson Mild K: Pooled analysis of two case-control studies on use of cellular and cordless telephones and the risk for malignant brain tumours diagnosed in 1997-2003. *Int Arch Occup Environ Health* 79:630-639, 2006
51. Hardell L, Carlberg M, Hansson Mild K: Pooled analysis of two-case control studies on the use of cellular and cordless telephones and the risk of benign brain tumours diagnosed during 1997-2003. *Int J Oncol* 28:509-518, 2006
52. Hepworth SJ, Schoemaker MJ, Muir KR, et al: Mobile phone use and risk of glioma in adults: Case-control study. *BMJ* 332:883-887, 2006
53. Klæboe L, Blaasaas KG, Tynes T: Use of mobile phones in Norway and risk of intracranial tumours. *Eur J Cancer Prev* 16:158-164, 2007
54. Hansson Mild K, Hardell L, Carlberg M: Pooled analysis of two Swedish case-control studies on the use of mobile and cordless telephones and the risk of brain tumours diagnosed during 1997-2003. *Int J Occup Saf Ergon* 13:63-71, 2007
55. Hardell L, Reizenstein J, Johansson B, et al: Angiosarcoma of the scalp and use of a cordless (portable) telephone. *Epidemiology* 10:785-786, 1999
56. Hardell L: No association between mobile phone usage and development of acoustic neuroma. *Evid-Based Healthcare* 8:213-215, 2004
57. Gale BD, Juran D: Cellular telephones and risk for brain tumors: A population-based, incident case-control study. *Neurology* 66:781, 2006
58. Vrijheid M, Deltour I, Krewski D, et al: The effects of recall errors and of selection bias in epidemiologic studies of mobile phone use and cancer risk. *J Expo Sci Environ Epidemiol* 16:371-384, 2006
59. Vrijheid M, Cardis E, Armstrong BK, et al: Validation of short term recall of mobile phone use for the Interphone study. *Occup Environ Med* 63:237-243, 2006
60. Johansen C, Boice JD Jr, McLaughlin J, et al: Mobile phones and malignant melanoma of the eye. *Br J Cancer* 86:348-349, 2002
61. Johansen C, Boice JD Jr, McLaughlin JK, et al: Use of cellular telephones and risk of cancer: A Danish cohort study. *Ugeskr Laeger* 164:1668-1673, 2002
62. Bersani F, Marinelli F, Ognibene A, et al: Intramembrane protein distribution in cell cultures is affected by 50 Hz pulsed magnetic fields. *Bioelectromagnetics* 18:463-469, 1997
63. Jin M, Lin H, Han L, et al: Biological and technical variables in myc expression in HL60 cells exposed to 60 Hz electromagnetic field. *Bioelectrochem Bioenerg* 44:210-217, 1997
64. Goodman R, Blank M: Insights into electromagnetic interaction mechanism. *J Cell Physiol* 192:16-22, 2002
65. Lai H, Singh NP: Acute low-intensity microwave exposure increase DNA single-strand breaks in rat brain cells. *Bioelectromagnetics* 16:207-210, 1995
66. Lai H, Singh NP: Single-and double-strand DNA breaks in rat brain cells after acute exposure to radiofrequency electromagnetic radiation. *Int J Radiat Biol* 69:513-521, 1996
67. Malyapa RS, Ahern EW, Bi C, et al: DNA damage in rat brain cells after in vivo exposure to 2450 MHz electromagnetic radiation and various methods of euthanasia. *Radiat Res* 149:637-645, 1998
68. Lagroye I, Anane R, Wettring BA, et al: Measurement of DNA damage after acute exposure to pulsed-wave 2450 MHz microwaves in rat brain cells by two alkaline comet assay methods. *Int J Radiat Biol* 80:11-20, 2004
69. Caraglia M, Marra M, Macinelli F, et al: Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi-chaperone complex in human epidermoid cancer cells. *J Cell Physiol* 204:539-548, 2005
70. Tillmann T, Ernst H, Ebert S, et al: Carcinogenicity study of GSM and DCS wireless communication signals in B6C3F1 mice. *Bioelectromagnetics* 173-187, 2007

Appendix

Table A1. Characteristics of Studies Included in the Final Meta-Analysis of Mobile Phone Use and Risk of Tumors

Study	Year of Publication	Country and Study Name	Study Design	Study Period	Study Length (years)	Type of Tumor	Type of Mobile Phone and Exposure
Hardell et al ⁷	1999	Sweden	PCC	1994-1996	2	Malignant and benign brain tumors (gliomas, meningiomas, and acoustic neuromas)	Cellular phone (analog and digital); latency period > 1 year v within 1 year
Muscat et al ⁸	2000	United States	HCC	1994-1998	4	Primary brain cancers (gliomas and other malignant brain tumors)	Handheld cellular phone; regular past or current use v never use
Inskip et al ⁹	2001	United States	HCC	1994-1998	4	Malignant and benign brain tumors (gliomas, meningiomas, and acoustic neuromas)	Handheld cellular phone; cumulative use of > 100 hours v never or rarely use
Stang et al ¹⁰	2001	Germany	HCC and PCC	1995-1998	3	Uveal melanomas	Mobile phone; possible/probable/certain ever exposure v never exposure
Auvinen et al ¹¹	2002	Finland	PCC	1996		Malignant and benign brain tumors (gliomas and meningiomas) and salivary gland cancers	Cellular phone (analog and digital); ever use v never use
Hardell et al ¹²	2002	Sweden	PCC	1997-2000	3	Malignant and benign brain tumors (gliomas, meningiomas, pituitary tumors, and acoustic neuromas)	Cellular or cordless phone (analog and digital); use v no use
Warren et al ¹³	2003	United States	HCC	1995-2000	5	Intratemporal facial nerve tumors	Handheld cellular phone; use v no use
Hardell et al ¹⁴	2004	Sweden	PCC	1994-2000	6	Malignant and benign salivary gland tumors	Cellular or cordless phone; use v no use
Hardell et al ¹⁵	2005	Sweden	PCC	1999-2002	3	Non-Hodgkin's lymphomas	Cellular or cordless phone (analog and digital); use v no use
Hardell et al ¹⁶	2005	Sweden	PCC	2000-2003	3	Benign brain tumors (meningiomas, acoustic neuromas, and other benign brain tumors)	Cellular or cordless telephone (analog and digital); use v no use
Schoemaker et al ¹⁷	2005	Five North European countries: Denmark, Finland, Norway, Stockholm, and United Kingdom; followed a protocol of the INTERPHONE Study	PCC	1999-2004	5	Benign brain tumors (acoustic neuromas)	Mobile phone (analog and digital); regular use v never or nonregular use
Hardell et al ¹⁸	2006	Sweden	PCC	2000-2003	3	Malignant brain tumors (gliomas and other malignant tumors)	Cellular or cordless phone (analog and digital); use v no use
Linnet et al ¹⁹	2006	United States	PCC	1998-2000	2	Non-Hodgkin's lymphomas	Cellular phone; lifetime ever use v never use

(continued on following page)

Table A1. Characteristics of Studies Included in the Final Meta-Analysis of Mobile Phone Use and Risk of Tumors (continued)

Study	OR	95% CI	Adjustment	Exposed		Unexposed	
				No. of Patient Cases	No. of Controls	No. of Patient Cases	No. of Controls
Hardell et al ⁷	0.98	0.69 to 1.41	Age, sex, and study region (matched)	78	161	131	264
Muscat et al ⁸	0.85*	0.6 to 1.2	Age, years of education, sex, race, study center, proxy subject, and month and year of interview	66	76	403	346
Inskip et al ⁹	0.9*	0.7 to 1.1	Date of interview, type of respondent, educational level, annual household income, type of health coverage, marital status, religion, history of radiotherapy to the head or neck, and handedness	52	54	637	625
Stang et al ¹⁰	2.8	1.0 to 7.9	Social class with 9 years at school or less	7	25	111	450
Auvinen et al ¹¹	Brain tumors: 1.3; salivary gland cancers: 1.3	Brain tumors: 0.9 to 1.8; salivary gland cancers: 0.4 to 4.7	Place of residence, occupation, and socioeconomic status	Brain tumors: 56; salivary gland cancers: 4	Brain tumors: 223; salivary gland cancers: 18	Brain tumors: 342; salivary gland cancers: 30	Brain tumors: 1,763; salivary gland cancers: 152
Hardell et al ¹²	Analog cellular phone: 1.3; digital cellular phone: 1.0*; cordless phone: 1.0*; combined OR: 1.15	Analog cellular phone: 1.04 to 1.6; digital cellular phone: 0.8 to 1.2; cordless phone: 0.8 to 1.2; combined OR: 0.99 to 1.33	Use of different types of phones	650	618	779	852
Warren et al ¹³	0.6	0.2 to 1.9	Age, sex, and race (matched)	5	53	13	88
Hardell et al ¹⁴	1.02*	0.75 to 1.38	Age and sex	91	352	176	701
Hardell et al ¹⁵	1.06*	0.87 to 1.31	Age, sex, and year of diagnosis (patient cases) or enrollment (controls)	607	695	303	321
Hardell et al ¹⁶	1.4*	1.03 to 1.9	Age, sex, socioeconomic index, and year of diagnosis	290	459	123	233
Schoemaker et al ¹⁷	0.9*	0.7 to 1.1	Highest educational level and combination of interview year and interview lag time	360	1,934	316	1,612
Hardell et al ¹⁸	1.9*	1.3 to 2.7	Age, sex, socioeconomic index, and the year of diagnosis	254	459	63	233
Linnet et al ¹⁹	1.0*	0.7 to 1.3	Age, race, education, and geographic site	317	247	234	215

(continued on following page)

Abbreviations: OR, odds ratio; PCC, population-based case-control study; HCC, hospital-based case-control study.
*Adjusted OR.

Meta-Analysis of Mobile Phone Use and Risk of Tumor

Table A1. Characteristics of Studies Included in the Final Meta-Analysis of Mobile Phone Use and Risk of Tumors (continued)

Study	Year of Publication	Country and Study Name	Study Design	Study Period	Study Length (years)	Type of Tumor	Type of Mobile Phone and Exposure
Lönn et al ²⁰	2006	Denmark and Sweden; part of the INTERPHONE Study	PCC	2000-2002	2	Malignant and benign parotid gland tumors	Mobile phone; regular use v never or rarely use
Schüz et al ²¹	2006	Germany; part of the INTERPHONE Study	PCC	2000-2003	3	Malignant and benign brain tumors (glioma and meningioma)	Cellular phone; ever regular use v never use
Takebayashi et al ²²	2006	Japan; followed a protocol of the INTERPHONE Study	PCC	2000-2004	4	Benign brain tumors (acoustic neuromas)	Mobile phone (analog and digital); regular use v no use
Hardell et al ²³	2007	Sweden	PCC	1993-1997	4	Testicular cancers (seminomas and nonseminomas)	Cellular or cordless phone; use v not use
Hours et al ²⁴	2007	France; part of the INTERPHONE Study	PCC	2001-2003	2	Malignant and benign brain tumors (gliomas, meningiomas, and acoustic neuromas)	Mobile phone; regular use v no or nonregular use
Lahkola et al ²⁵	2007	5 North European countries: Denmark, Finland, Norway, Sweden, and United Kingdom; followed a protocol of the INTERPHONE Study	PCC	2000-2004	4	Malignant brain tumors (gliomas)	Mobile phone (analog and digital); regular use v never or nonregular use
Lahkola et al ²⁶	2008	5 North European countries: Denmark, Finland, Norway, Sweden, and United Kingdom; followed a protocol of the INTERPHONE Study	PCC	2000-2004	4	Benign brain tumors (meningiomas)	Mobile phone (analog and digital); regular use v never or nonregular use
Sadetzki et al ²⁷	2008	Israel; followed a protocol of the INTERPHONE Study	PCC	2001-2003	2	Malignant and benign parotid gland tumors	Cellular phone; regular use v nonregular use (< 1 year)
Takebayashi et al ²⁸	2008	Japan; followed a protocol of the INTERPHONE Study	PCC	2000-2004	4	Malignant and benign brain tumors	Mobile phone (analog and digital); regular use v no use

(continued on following page)

Table A1. Characteristics of Studies Included in the Final Meta-Analysis of Mobile Phone Use and Risk of Tumors (continued)

Study	OR	95% CI	Adjustment	Exposed		Unexposed	
				No. of Patient Cases	No. of Controls	No. of Patient Cases	No. of Controls
Lönn et al ²⁰	0.80* (combined ORs of malignant parotid gland and benign pleomorphic adenoid)	0.54 to 1.20	Age, sex, geographic region, and education	102	603	70	399
Schüz et al ²¹	0.91* (combined ORs of glioma and meningioma)	0.75 to 1.1	Age, socioeconomic status, and living in a city	242	517	505	977
Takebayashi et al ²²	0.73*	0.43 to 1.23	Education and marital status	51	192	46	138
Hardell et al ²³	1.0*	0.8 to 1.2	Age, year of diagnosis, and cryptorchidism	372	358	516	512
Hours et al ²⁴	0.93*	0.69 to 1.27	Socioeconomic status, smoking status, and marital status	188	257	162	198
Lahkola et al ²⁵	0.78*	0.68 to 0.91	Education and family history of glioma	867	1,853	629	1,281
Lahkola et al ²⁶	0.76	0.65 to 0.89	Sex, 5-year age group, region, and county (matched)	573	1,696	631	1,249
Sadetzki et al ²⁷	0.87*	0.68 to 1.13	Cigarette smoking	285	691	175	575
Takebayashi et al ²⁸	0.87* (combined ORs of glioma, meningioma, and pituitary)	0.63 to 1.22	Education and marital status	173	329	139	224

Meta-Analysis of Mobile Phone Use and Risk of Tumor

Table A2. Mobile Phone Use of 10 Years or Longer (*v* never or rarely use) and the Risk of Tumors in Subgroup Meta-Analyses

Factor	No. of Studies	Summary OR	95% CI of OR	Heterogeneity, I ² (%)	Model Used
All*	13	1.18	1.04 to 1.34	33.1	Fixed effects
Research group					
Hardell et al*	7	1.35	1.14 to 1.59	35.1	Fixed effects
INTERPHONE	6	0.99	0.82 to 1.21	0	Fixed effects
Methodologic quality					
High (low bias: ≥ 7 points)*	8	1.32	1.12 to 1.54	29.1	Fixed effects
Hardell et al*	7	1.35	1.14 to 1.59	35.1	Fixed effects
INTERPHONE	1	1.10	0.70 to 1.80	NA	NA
Low (high bias: < 7 points, all INTERPHONE)	5	0.97	0.79 to 1.21	0	Fixed effects
Type of tumor					
Brain tumor*	8	1.24	1.00 to 1.55	50.8	Random effects
Hardell et al*	4	1.54	1.26 to 1.89	0	Fixed effects
INTERPHONE	4	1.00	0.81 to 1.22	10.9	Fixed effects
Other tumors†	5	1.00	0.76 to 1.30	0	Fixed effects
Hardell et al	3	1.00	0.74 to 1.35	0	Fixed effects
INTERPHONE	2	0.97	0.54 to 1.77	0	Fixed effects
Malignancy of tumor					
Malignant	7	1.15	0.78 to 1.71	58.8	Random effects
Hardell et al	4	1.42	0.94 to 2.14	54.5	Random effects
INTERPHONE	3	0.74	0.50 to 1.11	0	Fixed effects
Benign*	8	1.33	1.11 to 1.58	39.3	Fixed effects
Hardell et al*	3	1.66	1.32 to 2.09	1.9	Fixed effects
INTERPHONE	5	0.98	0.75 to 1.28	0	Fixed effects
Type of mobile phone					
Analog*	10	1.34	1.07 to 1.66	29.8	Fixed effects
Hardell et al*	7	1.52	1.19 to 1.95	0	Fixed effects
INTERPHONE	3	0.82	0.51 to 1.32	0	Fixed effects
Digital (all Hardell et al)*	3	1.68	1.01 to 2.81	0	Fixed effects
Laterality of tumor (all INTERPHONE)†					
Ipsilateral*	5	1.32	1.02 to 1.70	0	Fixed effects
Contralateral	4	0.89	0.68 to 1.15	0	Fixed effects

NOTE. All included studies were population-based case-control studies.

Abbreviations: OR, odds ratio; NA, not applicable.

*Statistically significant positive association.

†Salivary gland tumor, non-Hodgkin's lymphoma, and testicular tumor.

Table A3. Mobile Phone Use (versus never or rarely use) and the Risk of Brain Tumors in Subgroup Meta-Analyses

Factor	No. of Studies	Summary OR	95% CI of OR	Heterogeneity, I ² (%)	Model Used
All brain tumors	15	0.97	0.86 to 1.10	70.3	Random effects
Type of brain tumor					
Gliomas	10	1.09	0.89 to 1.34	67.9	Random effects
Hardell et al	3	1.37	0.88 to 2.12	68.5	Random effects
INTERPHONE*	4	0.84	0.75 to 0.96	33.9	Fixed effects
Other groups	3	1.06	0.76 to 1.48	51.3	Random effects
Meningiomas*	9	0.83	0.75 to 0.92	11.9	Fixed effects
INTERPHONE*	4	0.77	0.68 to 0.88	0	Fixed effects
Other groups	5	0.95	0.80 to 1.13	18.0	Fixed effects
Acoustic neuromas	6	0.94	0.79 to 1.11	5.4	Fixed effects
Hardell et al	2	1.38	0.92 to 2.08	0	Fixed effects
INTERPHONE	3	0.88	0.72 to 1.07	0	Fixed Effect
Other groups	1	0.80	0.50 to 1.40	NA	NA
Malignancy of brain tumor					
Malignant	7	0.99	0.79 to 1.23	74.1	Random effects
Hardell et al	3	1.26	0.88 to 1.81	74.9	Random effects
INTERPHONE*	2	0.77	0.65 to 0.91	0	Fixed effects
Other groups	2	0.87	0.67 to 1.14	0	Fixed effects
Benign*	12	0.87	0.80 to 0.95	31.0	Fixed effects
Hardell et al	3	1.16	0.96 to 1.40	17.5	Fixed effects
INTERPHONE*	6	0.80	0.72 to 0.89	0	Fixed effects
Other groups	3	0.82	0.61 to 1.11	0	Fixed effects
Type of mobile phone					
Analog	8	1.02	0.83 to 1.24	62.2	Random effects
Digital	10	0.92	0.79 to 1.07	62.5	Random effects
Laterality of brain tumor					
Ipsilateral	10	1.23	0.97 to 1.58	88.2	Random effects
Contralateral	8	0.92	0.74 to 1.15	82.0	Random effects
Research group					
Hardell et al†	4	1.29	1.02 to 1.64	64.6	Random effects
INTERPHONE*	7	0.82	0.76 to 0.89	0	Fixed effects
Other groups	4	0.96	0.81 to 1.13	31.7	Fixed effects
Methodologic quality					
High (low bias: ≥ 7 points)	5	1.19	0.96 to 1.49	71.7	Random effects
Hardell et al†	4	1.29	1.02 to 1.64	64.6	Random effects
INTERPHONE	1	0.90	0.70 to 1.10	NA	NA
Low (high bias: < 7 points)*	10	0.84	0.78 to 0.91	16.2	Fixed effects
INTERPHONE*	6	0.81	0.75 to 0.89	0	Fixed effects
Other groups	4	0.96	0.81 to 1.13	31.7	Fixed effects
Interview blinded to patient case/control status					
Blinded (all Hardell et al)†	4	1.29	1.02 to 1.64	64.6	Random effects
Not blinded or no description*	11	0.85	0.79 to 0.91	9.5	Fixed effects
INTERPHONE*	7	0.82	0.76 to 0.89	0	Fixed effects
Other groups	4	0.96	0.81 to 1.13	31.7	Fixed effects

Abbreviations: OR, odds ratio; NA, not applicable.

*Statistically significant negative association.

†Statistically significant positive association.

Meta-Analysis of Mobile Phone Use and Risk of Tumor

Table A4. Mobile Phone Use (v never or rarely use) and the Risk of Tumors Other Than Brain Tumors in Subgroup Meta-Analyses

Factor	No. of Studies	Summary OR	95% CI of OR	Heterogeneity, I ² (%)	Model Used
All	8	0.99	0.89 to 1.10	0	Fixed effects
Type of tumor					
Salivary gland tumor	4	0.91	0.76 to 1.08	0	Fixed effects
Non-Hodgkin's lymphoma	2	1.04	0.88 to 1.24	0	Fixed effects
Testicular cancer	1	1.00	0.80 to 1.20	NA	NA
Uveal melanoma*	1	2.80	1.00 to 7.90	NA	NA
Malignancy of tumor					
Malignant	8	1.02	0.91 to 1.15	0	Fixed effects
Hardell et al	3	1.03	0.90 to 1.17	0	Fixed effects
INTERPHONE	2	0.84	0.54 to 1.31	0	Fixed effects
Other groups	3	1.10	0.82 to 1.47	44.1	Fixed effects
Benign	3	0.90	0.70 to 1.15	0	Fixed effects
Hardell et al	1	2.03	0.55 to 7.50	NA	NA
INTERPHONE	2	0.87	0.68 to 1.12	0	Fixed effects
Type of mobile phone					
Analog	4	0.80	0.62 to 1.04	0	Fixed effects
Hardell et al	3	0.80	0.61 to 1.03	0	Fixed effects
Other group	1	1.00	0.30 to 4.00	NA	NA
Digital	4	1.10	0.89 to 1.31	0	Fixed effects
Hardell et al	3	1.07	0.88 to 1.30	0	Fixed effects
Other group	1	1.70	0.20 to 16.00	NA	NA
Laterality of tumor (all INTERPHONE)					
Ipsilateral	2	1.12	0.89 to 1.42	24.7	Fixed effects
Contralateral	2	0.78	0.60 to 1.01	20.6	Fixed effects
Research group					
Hardell et al	3	1.03	0.90 to 1.17	0	Fixed effects
INTERPHONE	2	0.85	0.69 to 1.05	0	Fixed effects
Other groups	3	1.10	0.82 to 1.47	44.1	Fixed effects
Methodologic quality					
High (low bias: ≥ 7 points)	3	1.02	0.90 to 1.17	0	Fixed effects
Hardell et al	2	1.03	0.89 to 1.19	0	Fixed effects
Other group	1	1.00	0.70 to 1.30	NA	NA
Low (high bias: < 7 points)	5	0.94	0.79 to 1.11	31.1	Fixed effects
Hardell et al	1	1.02	0.75 to 1.38	NA	NA
INTERPHONE	2	0.85	0.69 to 1.05	0	Fixed effects
Other groups	2	2.04	0.92 to 4.50	0	Fixed effects
Interview blinded to patient case/control status					
Blinded	4	1.04	0.92 to 1.19	19.3	Fixed effects
Hardell et al	3	1.03	0.90 to 1.17	0	Fixed effects
Other group*	1	2.80	1.00 to 7.90	NA	NA
Not blinded or no description	4	0.90	0.76 to 1.07	0	Fixed effects
INTERPHONE	2	0.85	0.69 to 1.05	0	Fixed effects
Other groups	2	1.02	0.75 to 1.37	0	Fixed effects

Abbreviations: OR, odds ratio; NA, not applicable.

*Statistically significant positive association.